Research and Publications — Ilmiy Nashrlar Markazi
Bosh sahifa

ВЛИЯНИЕ ТЕРАПИИ ЭМПАГЛИФЛОЗИНОМ НА ПЛОЩАДЬ ЖИРОВОЙТКАНИ У ЛИЦ С ХСН И ХБП: БИОИМПЕДАНСНЫЙ АНАЛИЗ

ID: GEN-2026-321DOI 10.5281/zenodo.20284824CC-BY-4.0

Authors (1)

Худойбердиева Г.А.Corresponding

Received

Received

Revised

Revised

Accepted

Accepted

Published

May 19, 2026

Abstract

Maqolada empagliflozinning surunkali yurak yetishmovchiligi (SYE) va surunkali buyrak kasalligi (SBK) bo‘lgan bemorlarda yog‘ to‘qimasiga ta’siri o‘rganilgan. 6 oylik davolashdan so‘ng bioimpedansometriya umumiy, visseral va teri osti yog‘ massasi sezilarli darajada kamayganini, kardiometabolik ko‘rsatkichlarning yaxshilanganini va buyrak filtrlash tezligiga (SKF) sezilarli ta’sir ko‘rsatmaganini ko‘rsatdi. Empagliflozin istiqbolli dori sifatida ko‘rib chiqilib, qo‘shimcha tadqiqotlarni talab qiladi.

Keywords

Original

surunkali yurak yetishmovchiligisurunkali buyrak kasalligiempagliflozinbioimpedansometriyavisseral yog‘kardiometabolik xavf

Cite this article

Г.А., Х. (2026). ВЛИЯНИЕ ТЕРАПИИ ЭМПАГЛИФЛОЗИНОМ НА ПЛОЩАДЬ ЖИРОВОЙТКАНИ У ЛИЦ С ХСН И ХБП: БИОИМПЕДАНСНЫЙ АНАЛИЗ. Research and Publications. https://doi.org/10.5281/zenodo.20284824

References

  1. [1]Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Ruilope LM, et al. Cardiovascular and kidney outcomes with finerenone in patients with CKD and type 2 diabetes: TA’LIM FIDOYILARI FIDELIO-DKD trial. Kidney Int. 2019;96(2):469-481. doi:10.1016/j.kint.2019.11.028.
  2. [2]Bakris G.L. et al. (2021). Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 383, pp. 2219-2229.
  3. [3]Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956.
  4. [4]Bhatt D.L. et al. (2021). Sotagliflozin Reduces Heart Failure Events in Patients with Diabetes and CKD Regardless of Albuminuria Status. Journal of the American College of Cardiology, 78(1), pp. 101-110.
  5. [5]Cooper M.E. et al. (2021). The Interplay between Diabetes, Heart Failure, and Chronic Kidney Disease: Mechanisms and Therapeutic Implications. Diabetologia, 64(2), pp. 271-281.
  6. [6]Eckardt, K. U., et al. The Importance of Nephrologist-Cardiologist Collaboration in Managing Patients with Cardiorenal Syndrome. Kidney International, vol. 99, no. 2, 2021, pp. 276-288.
  7. [7]Filippatos G., Anker S.D., Böhm M. et al. (2022). Benefits of Finerenone to Improve Outcomes in Patients With Kidney Disease Diabetes. Journal of the American College of Cardiology, 79(12), pp. 1508-1518.
  8. [8]Heerspink H.J.L. et al. (2021). Rationale and Design of the EMPA-KIDNEY Study. Clinical Journal of the American Society of Nephrology, 16(1), pp. 124-136.
  9. [9]Jardine M.J. et al. (2021). The Role of Finerenone in Cardiorenal Protection. Lancet Diabetes & Endocrinology, 9(7), pp. 649-659.
  10. [10]Kemp C.D., Conte J.V. (2021). The Pathophysiology of Heart Failure. Cardiovascular Pathology, 30(2), pp. 79-89.
External sourceDOI: 10.5281/zenodo.20284824